NEWS
Ultimovacs enters the Oslo Stock Exchange
Oslo Cancer Cluster member Ultimovacs entered the Oslo Stock Exchange on Monday 3 June 2019.
Learning about the human brain
Oslo Cancer Cluster and Ullern Upper Secondary School arranged a work placement for students to learn about neuroscience at the University of Oslo.
A successful first quarter for Nordic Nanovector
Nordic Nanovector raises NOK 225 million in private placements, has Phase II clinical trials in 74 sites in 23 countries and prepares to commercialize the company.
Introducing programming to the curriculum
Programming is not just for computer hackers, it can also help teachers to engage their students in science subjects.
How will biobanks accelerate cancer research?
Biobanks – the powerful tools in cancer research you may have never heard of.
Kronikk: Dine helsedata kan styrke helsenæringen
Vi får nye forretningsmodeller innen helse som er basert på digitalisering og persontilpasset medisin. Her kan Norge virkelig lede an!
Radforsk to invest NOK 4.5 million in cancer research
Radforsk, a partner of Oslo Cancer Cluster, is awarding several million Norwegian kroner to new research that fights cancer with light.
Should Norway implement a clinical trial league table?
We asked four MBA students from Cambridge University to evaluate how patient recruitment practices in Norway can be improved.
Hvordan gjør vi våre mest intime data til gull?
Helsedata er en voksende gullåre, men vi kan ikke grave i den uten videre.
